# GHK-Cu References: The Cited Research Record

> GHK-Cu references: the full cited literature behind this digest, from Maquart 1988 and Pickart's reviews to the 2024-2025 colitis, neuroprotection and anti-wrinkle studies.

Every study cited on this site, indexed with DOI and PubMed/PMC links — the source record behind each GHK-Cu benchmark reported here.

## How to read these GHK-Cu references

These GHK-Cu references are the complete source list for the numbers reported across this site. Each inline [N] marker on the research, skin, hair, dosage and FAQ pages resolves to an entry below, with a DOI and a PubMed or PMC URL so any claim can be checked at the primary source. The list spans the foundational work — Maquart's 1988 fibroblast collagen study [1] and Pickart's tissue-remodeling and gene reviews [2][6] — through the 2024-2025 colitis, neuroprotection and anti-wrinkle literature [13][14][15]. The same citations underpin the [GHK-Cu wound-healing research](/research) and the [GHK-Cu safety and copper toxicity](/faq) discussions elsewhere on the site.

Two cautions belong with the list. A large share of the foundational GHK-Cu mechanistic and review literature originates from a single investigator, Loren Pickart (1938-2023), and colleagues, so independent replication of the broader gene-expression and anti-aging claims is limited [2][6]. And the genome-wide signature is bioinformatic — derived largely from Connectivity Map analyses that still need protein-level in vivo validation [2]. The independent emphysema-gene-reversal [9] and the non-Pickart fibrosis [8], colitis [14] and neuroprotection [15] studies are noted here because they widen that evidentiary base.

## Regulatory status of the cited compound

For context on the record below: there is no FDA- or EMA-approved therapeutic indication for GHK-Cu by any route. Topical Copper Tripeptide-1 is a legal cosmetic ingredient with a long safety record; injectable, oral and other systemic uses are unapproved and research-only [6]. One topical wound-healing trial (CuHeal, NCT07437586) has been registered, but there are no completed Phase 2/3 trials for systemic or injectable GHK-Cu. The references are the published research record — not evidence of an approved use.

## References

[1] Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. https://pubmed.ncbi.nlm.nih.gov/3169264/
[2] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
[3] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[4] Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Ann Dermatol. 2016;28(4):438-443. https://pmc.ncbi.nlm.nih.gov/articles/PMC4969472/
[5] Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. https://pmc.ncbi.nlm.nih.gov/articles/PMC3016279/
[6] Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. https://pubmed.ncbi.nlm.nih.gov/18644225/
[7] Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832. https://pmc.ncbi.nlm.nih.gov/articles/PMC3359723/
[8] Zhou XM, et al. GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFbeta1/Smad-Mediated Epithelial-to-Mesenchymal Transition. Front Pharmacol. 2017;8:904. https://pmc.ncbi.nlm.nih.gov/articles/PMC5733019/
[9] Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. https://pmc.ncbi.nlm.nih.gov/articles/PMC4064320/
[10] Bobyntsev II, Chernysheva OI, Dolgintsev ME, Smakhtin MY, Belykh AE. Anxiolytic effects of Gly-His-Lys peptide and its analogs. Bull Exp Biol Med. 2015;158(6):726-728. https://pubmed.ncbi.nlm.nih.gov/25900608/
[11] Sever'yanova LA, Dolgintsev ME. Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats. Bull Exp Biol Med. 2017;164(2):140-143. https://pubmed.ncbi.nlm.nih.gov/29181666/
[12] Arul V, Kartha R, Jayakumar R. Biotinylated GHK peptide incorporated collagenous matrix: A novel biomaterial for dermal wound healing in rats. J Biomed Mater Res B Appl Biomater. 2005;73(2):383-391. https://pubmed.ncbi.nlm.nih.gov/15803494/
[13] Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11830136/
[14] Mao S, Huang J, Li J, Sun F, Zhang Q, Cheng Q, Zeng W, Lei D, Wang S, Yao J. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Front Pharmacol. 2025;16:1551843. https://pmc.ncbi.nlm.nih.gov/articles/PMC12263609/
[15] Min JH, Sarlus H, Harris RA. Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro. Metallomics. 2024;16(4):mfae019. https://pubmed.ncbi.nlm.nih.gov/38599632/

---

A benchmark sheet for the GHK-Cu copper-tripeptide literature — every study clocked, every number cited, and no clinic behind the console.